22:35 , Jul 19, 2019 |  BioCentury  |  Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

A draft FDA guidance for heart failure endpoints could spark investment and accelerate development of cardiovascular therapies. But companies still don’t have a clear sense of when and whether they’ll need to gather mortality data...
23:58 , Nov 28, 2018 |  BC Extra  |  Preclinical News

Placental organoid could improve preeclampsia therapies

A placenta-like organoid developed by a University of Cambridge team could improve understanding of maternal-fetal first-trimester disorders like preeclampsia and provide a model to study therapies to treat first-trimester complications. Challenges in preeclampsia and other...
20:29 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer In silico , cell culture and mouse studies suggest digoxin could help treat group 3 or 4 medulloblastoma. In silico screening of 1,309 FDA-approved small molecule drugs for compounds predicted to modulate...
19:52 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Velo begins Phase IIb/III for digoxin immune fab to treat severe preeclampsia

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) said Velo Bio LLC (Morrisville, N.C.) began a double-blind, U.S. Phase IIb/IIIa trial to evaluate digoxin immune fab (DIF, DigiFab) in about 200 antepartum women with severe preeclampsia. AMAG has an...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MEK; BRAF

Cancer INDICATION: Melanoma; acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest combining digitoxin or digoxin with MEK and/or BRAF inhibitors could help treat melanoma and AML. In primary tumor cells from...
07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Apr 21, 2016 |  BC Innovations  |  Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

Covis, Concordia Healthcare deal

Concordia will acquire Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis expects to record $47-$52 million in revenue related to the acquired products. The deal includes Nilandron...
08:00 , Nov 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Adducin 1 (ADD1); ATPase Na+/K+ transporting a2 polypeptide (ATP1A2) In vitro and mouse studies suggest inhibiting ADD1 or ATP1A2 could help...
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma ATPase Na+/K+ transporting a2 polypeptide (ATP1A2) In vitro and rabbit studies have identified selective inhibitors of ATP1A2 that could be useful for treating...